This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

WILLIAM BANNER, JR, MD, PHD; C. GEORGE RAY, MD

Am J Dis Child. 1984;138(1):14-16.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In this issue of the AJDC, Odio et al¹ and Alpert et al² report disturbing observations concerning the clinical use of vancomycin hydrochloride. The pharmaceutical formulation of vancomycin has been vastly improved in recent years, and the more uniform

preparation has been considered reasonably safe when administered and monitored appropriately. However, concerns about the safety of vancomycin raised in this issue of the JOURNAL argue for an analysis of its usefulness and limitations.

HISTORY

Vancomycin was first isolated in 1956 in the Eli Lilly & Co, laboratories, Indianapolis, from strains of Streptomyces orientalis. It began to be used clinically in the late 1950s, particularly for serious infections caused by staphylococci, in which penicillin and other antimicrobial agents were often ineffective. The original pharmaceutical preparation was extremely irritating to veins—a vexation for patients, as well as clinicians and nurses. Some clinicians, not very affectionately, called the preparation "Mississippi mud" . . . [Full Text PDF of this Article]

Author Affiliations
Departments of Pediatrics, Pharmacology, and Pathology Arizona Health Sciences Center 1501 N Campbell Ave Tucson, AZ 85724

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?